Navigation Links
Celsis IVT Wins Preliminary Injunction Against Life Technologies and CellzDirect in Liverpool™ Patent Infringement Lawsuit
Date:9/10/2010

CHICAGO, Sept. 10 /PRNewswire/ -- Celsis In Vitro, Inc. (Celsis IVT) announced today that the United States District Court for the Northern District of Illinois in Chicago has entered a preliminary injunction against CellzDirect Inc., Invitrogen Corporation, and Life Technologies (the Defendants) due to their infringement of U.S. Patent No. 7,604,929 (the Liverpool™ patent).  Life Technologies of Carlsbad, California (Nasdaq: LIFE) is the parent of Invitrogen and CellzDirect.  The Liverpool patent relates to methods for producing multi-cryopreserved hepatocytes and methods for using multi-cryopreserved hepatocytes to investigate in vitro drug metabolism.

According to the terms of the injunction, the Defendants and those acting in collaboration with them are enjoined from using the claimed methods of the Liverpool patent that relate to producing multi-cryopreserved hepatocytes and the use of multi-cryopreserved hepatocytes to investigate in vitro drug metabolism.  The Defendants are further barred from selling or offering to sell multi-cryopreserved hepatocytes including restrictions on products presently held in inventory.

In addition, the Defendants and those acting in collaboration with them are enjoined from inducing, aiding and abetting, or encouraging others to practice the claimed methods related to the use of multi-cryopreserved hepatocytes to investigate in vitro drug metabolism; for example by encouraging or supporting their customers who are in possession of Defendant-branded multi-cryopreserved products in their continued use to investigate in vitro drug metabolism.

Celsis IVT has alleged that certain processes and methods performed by CellzDirect and Invitrogen associated with their in vitro drug testing services and their pooled cryopreserved hepatocyte products willfully infringe one or more c
'/>"/>

SOURCE Celsis In Vitro, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui
2. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
3. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
4. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
5. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
6. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
7. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
8. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
9. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
10. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
11. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014   Ventana Medical Systems, Inc.  (Ventana), ... has entered into an agreement with Merck KGaA, Darmstadt, ... Serono in the United States ... Merck KGaA,s biopharmaceutical division on the development and commercialization ... using Ventana,s proprietary diagnostic assays. In alignment with Merck ...
(Date:7/10/2014)... Decision Resources Group finds that over half ... and Drug Administration,s (FDA) approval of Vifor Fresenius Medical ... approved by the FDA in November 2013 for the ... on dialysis. Other key findings from the ... : , Bundling: ...
(Date:1/15/2014)... Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition of ... Size, Share, Growth, Trends And Forecast, 2013 - 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 ) Dental consumables ... to treat dental impairments, for tooth restoration and in ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
... schools across the country, teachers are directed to send students ... have a vision issue.  This could be due to the ... the blackboard, poor performance in class or disruptive behavior. The ... difficult and that student could end up in the principal,s ...
... largest professional network for physicians, announced today ... power their medical expert searches. These firms are the ... million in honoraria to physicians last year. Using Doximity,s ... of over 30,000 physician experts. For physicians,  ...
Cached Medicine Technology:Disruptive Students May Not Be Able to See Their Problem 2Disruptive Students May Not Be Able to See Their Problem 3Disruptive Students May Not Be Able to See Their Problem 4Doximity Launches ExpertFinder to Match Clinical Need with Clinical Experts 2
(Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special ... new range of gorgeous Quinceanera dresses . ... for elegant Quinceanera outfits is huge. Therefore, 2014QuinceaneraDresses.com ... the company’s newly released dresses are made according ... elegant and vivid. , It is worthy ...
(Date:7/13/2014)... imaging device developed at Cedars-Sinai can provide early ... brain and are a classic sign of Alzheimer,s ... a clinical trial in Australia. , The researchers ... oral presentation at the Alzheimer,s Association International Conference ... by conference organizers to participate in a "breaking ...
(Date:7/13/2014)... 2014 Celebrity fitness trainer and former ... promotional partnership with Aqua Health Labs for their flagship ... supplement . The collaboration was recently announced live on ... trainer , actor, model, and a two time World ... celebrities, he has prepared stars including Demi Moore, Hilary ...
(Date:7/13/2014)... Seattle, Wa (PRWEB) July 13, 2014 ... updated by Vkool.com, this is a comprehensive guide that ... to deal with KP (keratosis pilaris). This ...     Chapter 1: What Is Keratosis Pilaris? ,     Chapter ... Do I Know If I Have KP? , ...
(Date:7/12/2014)... July 12, 2014 The Chicken ... the past five years, buoyed by stable demand for ... management system. “Eggs are a relatively affordable staple for ... egg consumption generally grows in line with the size ... McKitterick. Furthermore, demand for new specialty egg products with ...
Breaking Medicine News(10 mins):Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3
... acoustic guitars to wounded guitar-playing service members as part of a ... in San Antonio, TX. , ... Pasadena, CA (PRWEB) ... will present over twenty new acoustic guitars to wounded guitar-playing service ...
... siRNA drug delivered systemically, FREMONT, Calif., June ... U.S. Food and Drug Administration (FDA) has,approved the ... drug candidate, DGFi, in kidney transplantation. The Company ... Delayed Graft,Function (DGF) in kidney transplant patients to ...
... at the Silicom Ventures Summit on June 29th-30th in Tel Aviv. ... ... Mind Ltd (SoM) was selected to present its concept and system for ... in Tel Aviv, Israel. The developed system, called SoM-ToUR, is based on ...
... condition a public health priority , , THURSDAY, June 26 ... kidney disease (CKD) is increasing, and the fact it raises ... public health priority, say Taiwanese researchers. , They analyzed data ... part in a standard medical screening program in 1994. The ...
... in the United States in recent years even though the ... by researchers at the Johns Hopkins Bloomberg School of Public ... percent among black men ages 25 to 44 and 12 ... is published in Online First edition of the Journal ...
... June 26 "The only way to flatten ... was the overriding,sentiment at last week,s I3 (insight, ... This statement made by keynote speaker,Wally Gomaa, president ... hospitals and employers must begin (or continue) working,together ...
Cached Medicine News:Health News:Freedom Celebration - Gibson Guitar to Provide Instruments for the Wounded 2Health News:Freedom Celebration - Gibson Guitar to Provide Instruments for the Wounded 3Health News:Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi 2Health News:Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi 3Health News:Step of Mind Ltd Will Present its Concept at the Silicom Ventures Summit 2Health News:Chronic Kidney Disease Growing Globally 2Health News:Researchers study hidden homicide trend 2Health News:Aegis Health Group Revealed Next Generation of Employer-Based Health-Improvement Strategies at Nashville Conference 2
... The PRIMATOM System is a multifunctional ... PRIMUS Linear Accelerator and a SOMATOM ... technology brings image guidance to radiation ... target localization within the treatment room. ...
... SOMATOM Sensation is the highly respected ... coronary branches to visualizing plaque. With its ... industrys fastest rotation time of 0.33s, virtually ... z-Sharp Technology, the system delivers unprecedented diagnostic ...
... The DGH Technology, Inc. Pachmate (DGH 55) ... 6.9 inches long and 3.6 ounces in weight. ... accurate reliable corneal thickness measurements. The Pachmate ... shirt pocket. The Pachmate is rugged in ...
... integrated system that will perform venous occlusion ... You no longer need to manually control ... with and without reactive hyperemia are included. ... for measurements and the frequency with which ...
Medicine Products: